Back to top
more

ABIOMED, Inc. (ABMD)

(Real Time Quote from BATS)

$322.56 USD

322.56
52,793

-1.22 (-0.38%)

Updated Feb 25, 2021 12:17 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 253)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

Abiomed (ABMD) Posts Upbeat Impella SmartAssist Study Results

The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.

Stock Market News for Jan 29, 2021

U.S. stock markets closed higher on Thursday, recovering some of the sharp losses from the previous session

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3

ABIOMED's (ABMD) international Impella revenues improve in Q3.

Abiomed (ABMD) Q3 Earnings and Revenues Beat Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?

The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.

Sriparna Ghosal headshot

3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Abiomed's (ABMD) ECMO Technology Completes Successful Treatment

Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.

4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021

Four large-cap MedTech stocks are currently flourishing on the back of several positive developments

Sriparna Ghosal headshot

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus

Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic

Urmimala Biswas headshot

3 Best Buys from the Prospering Medical Instruments Industry

Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2

ABIOMED's (ABMD) international Impella revenues improved in Q2.

Abiomed (ABMD) Q2 Earnings and Revenues Surpass Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Oct 29 Earnings Roster: SYK, BAX & More

Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

Analysts Estimate Abiomed (ABMD) to Report a Decline in Earnings: What to Look Out for

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IART vs. ABMD: Which Stock Is the Better Value Option?

IART vs. ABMD: Which Stock Is the Better Value Option?

Trina Mukherjee headshot

3 MedTech Outperformers to Grab Amid Coronavirus Pandemic

Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.

Why Is Abiomed (ABMD) Down 12.4% Since Last Earnings Report?

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed

The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed

Urmimala Biswas headshot

MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential

MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

Abiomed (ABMD) Tops Q1 Earnings and Revenue Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.